Syncom Formulations (India) profit and loss

Latest FY26

Revenue: ₹489cr+5.2% on FY25
EBITDA: ₹77.4cr+43.0% on FY25
Net profit: ₹76.4cr+54.6% on FY25
EPS: ₹0.81+42.1% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

Expenses
	498	489	465	263	224
	33.1	31.3	17.4	13.5	14.6
	531	521	482	277	239
	220	221	278	132	99.5
	69.8	67.2	40.0	27.1	42.6
	−8.9	−3.9	−10.7	−1.8	−0.4
	68.3	67.1	52.2	35.1	25.9
	1.1	1.2	0.9	4.5	3.1
	6.7	6.5	5.2	4.7	4.5
	60.7	60.4	51.4	41.8	37.1
	418	419	417	243	212
	87.8	77.4	54.1	29.6	19.6
	81.1	70.9	48.9	24.9	15.1
Profit
	113	101	65.5	34.0	26.6
	−0.0	0.0	0.0	−0.0	0.0
	113	101	65.5	34.0	26.6
	25.8	22.9	14.7	8.1	6.7
	1.7	1.8	1.3	0.6	−0.2
	27.5	24.7	16.1	8.6	6.5
	85.5	76.4	49.4	25.3	20.1
	85.5	76.4	49.4	25.3	20.1
	−3.8	−3.6	4.6	6.8	2.0
	81.7	72.8	54.0	32.1	22.0
	—	76.4	—	—	—
Per share
	₹0.94	₹0.81	₹0.57	₹0.34	₹0.24
	₹0.94	₹0.81	₹0.57	₹0.34	₹0.24
Other comprehensive income — detail
	−3.8	−3.6	4.6	—	—
	−3.8	−3.6	4.6	6.8	2.0
Per share — as-filed variants
	₹0.94	₹0.81	₹0.57	₹0.34	₹0.24
	₹0.94	₹0.81	₹0.57	₹0.34	₹0.24
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	217	205	158	107	82.6
	43.6%	41.9%	33.9%	40.4%	36.8%
Adjusted (ex-exceptional items) — derived
	113	101	65.5	34.0	26.6
	−0.0	0.0	0.0	−0.0	0.0
	85.5	76.4	49.4	25.3	20.1
	₹0.94	₹0.81	₹0.57	₹0.34	₹0.24

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNCOMF₹20.33

Syncom Formulations (India) Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersHESTERBIO NGLFINE WINDLAS JAGSNPHARMAMRUTANJAN INDOCO SAIPARENTMcap ₹1,911 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	224.3	263.4	465.0	489.2	497.8
Other Income	14.6	13.5	17.4	31.3	33.1
Total Income	238.9	276.9	482.4	520.5	530.9
Expenses
+ Cost of Materials Consumed	99.5	131.5	278.0	220.9	220.1
+ Purchases of Stock-in-Trade	42.6	27.1	40.0	67.2	69.8
+ Changes in Inventories	-0.4	-1.8	-10.7	-3.9	-8.9
+ Employee Benefit Expense	25.9	35.1	52.2	67.1	68.3
+ Finance Costs	3.1	4.5	0.9	1.2	1.1
+ Depreciation & Amortisation	4.5	4.7	5.2	6.5	6.7
+ Other Expenses	37.1	41.8	51.4	60.4	60.7
Total Expenses	212.3	242.9	416.9	419.4	417.8
EBITDA	19.6	29.6	54.1	77.4	87.8
EBIT	15.1	24.9	48.9	70.9	81.1
Profit
PBT before Exceptional Items	26.6	34.0	65.5	101.1	113.1
+ Exceptional Items	0.0	-0.0	0.0	0.0	-0.0
Pretax Income	26.6	34.0	65.5	101.1	113.1
+ Current Tax	6.7	8.1	14.7	22.9	25.8
+ Deferred Tax	-0.2	0.6	1.3	1.8	1.7
Tax Expense	6.5	8.6	16.1	24.7	27.5
Net Income	20.1	25.3	49.4	76.4	85.5
+ Net Income — Continuing Ops	20.1	25.3	49.4	76.4	85.5
+ Other Comprehensive Income	2.0	6.8	4.6	-3.6	-3.8
Total Comprehensive Income	22.0	32.1	54.0	72.8	81.7
Net Income to Common	—	—	—	76.4	—
Per Share
Basic EPS	0.24	0.34	0.57	0.81	0.94
Diluted EPS	0.24	0.34	0.57	0.81	0.94
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	4.6	-3.6	-3.8
+ Items to be Reclassified to P&L	2.0	6.8	4.6	-3.6	-3.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	0.24	0.34	0.57	0.81	0.94
Diluted EPS — Continuing Operations	0.24	0.34	0.57	0.81	0.94
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	82.6	106.5	157.7	204.9	216.8
Gross Margin %	36.81	40.44	33.91	41.89	43.56
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	26.6	34.0	65.5	101.1	113.1
− Exceptional Items (reconciliation)	0.0	-0.0	0.0	0.0	-0.0
Net Income Adj (tax-effected)	20.1	25.3	49.4	76.4	85.5
EPS Adj	0.24	0.34	0.57	0.81	0.94
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	—	1.00	1.00
Paid Up Equity Capital	94.0	94.0	—	94.0	94.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.